China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) just unveiled an update.
China Resources Pharmaceutical Group Ltd. reported its annual financial results for the year ending December 31, 2024, showing a revenue increase to RMB 257.67 billion from RMB 244.70 billion in 2023. The company’s profit for the year rose to RMB 8.40 billion, with a notable contribution from non-controlling interests. Despite increased selling, distribution, and administrative expenses, the company managed to improve its gross profit, indicating a strong operational performance.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. The company is known for its comprehensive range of healthcare products and services, catering to a broad market segment.
YTD Price Performance: -5.15%
Average Trading Volume: 2,135
Technical Sentiment Signal: Sell
Current Market Cap: €4.13B
Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.